17 patents
Utility
P97 fusion proteins
9 May 23
Provided are p97 (melanotransferrin)-trastuzumab fusion proteins and related methods of use thereof, for instance, to facilitate delivery of trastuzumab across the blood-brain barrier (BBB) and/or improve tissue penetration of the antibody in CNS and peripheral tissues, and thereby treat and/or diagnose HER2-positive cancers, including those of the central nervous system (CNS).
Timothy Z. Vitalis, Reinhard Gabathuler
Filed: 10 Feb 19
Utility
Treatment of Lymphatic Metastases
26 May 22
Disclosed are therapeutic payloads comprising p97 fragments coupled with active agents having blood-brain barrier (BBB) transport activity, including variants and combinations thereof, to facilitate delivery of therapeutic or diagnostic agents across the BBB.
Mei Mei Tian, Mark Day
Filed: 19 Jul 19
Utility
Bifunctional Blood Brain Therapies for INTERLEUKIN-1 Related Diseases
12 May 22
Disclosed are therapeutic payloads comprising p97 fragments coupled with active agents having blood-brain barrier (BBB) transport activity, including variants and combinations thereof, to facilitate delivery of therapeutic or diagnostic agents across the BBB.
Mei Mei Tian
Filed: 28 Jan 22
Utility
Combination Therapies for Delivery Across the Blood Brain Barrier
17 Feb 22
Provided are compositions and methods related to the co-administration of an immunoglobulin Fc region-containing polypeptide and a central nervous system (CNS)-targeted antibody or Fc-fusion polypeptide conjugate, to improve pharmacokinetics and/or delivery of the conjugate across the blood-brain barrier (BBB).
Reinhard Gabathuler, Mei Mei Tian
Filed: 13 Aug 21
Utility
Compositions and Methods for Treating Frontotemporal Dementia
23 Dec 21
Disclosed are therapeutic payloads comprising p97 fragments coupled with active agents having blood-brain barrier (BBB) transport activity, including variants and combinations thereof, to facilitate delivery of therapeutic or diagnostic agents across the BBB.
Deborah Rathjen, Mei Mei Tian
Filed: 15 Jun 21
Utility
Dephosphorylated Lysosomal Storage Disease Proteins and Methods of Use Thereof
16 Dec 21
Provided are substantially dephosphorylated forms of lysosomal storage disease (LSD) proteins, including dephosphorylated forms of iduronate-2-sulfatase (IDS, or 12D) and iduronidase (IDU), having increased ability to traverse or penetrate the blood brain barrier (BBB) relative to phosphorylated forms of the protein, and p97 conjugates thereof.
Timothy Vitalis, Reinhard Gabathuler
Filed: 11 Jun 21
Utility
Compositions and Methods for Treating Lewy Body Dementia
18 Nov 21
Disclosed are therapeutic payloads comprising p97 fragments coupled with active agents having blood-brain barrier (BBB) transport activity, including variants and combinations thereof, to facilitate delivery of therapeutic or diagnostic agents across the BBB.
Deborah Ann Rathjen, Mei Mei Tian
Filed: 14 May 21
Utility
P97-IDS fusion proteins
21 Sep 21
Provided are fusion proteins between p97 (melanotransferrin) and iduronate-2-sulfatase (IDS), and related compositions and methods of use thereof, for instance, to facilitate delivery of IDS across the blood-brain barrier (BBB) and/or improve its tissue penetration in CNS and/or peripheral tissues, and thereby treat and/or diagnose Hunter Syndrome (Mucopolysaccharidosis type II; MPS II) and related lysosomal storage disorders, including those having a central nervous system (CNS) component.
Timothy Z. Vitalis, Reinhard Gabathuler
Filed: 22 Jun 19
Utility
Dephosphorylated lysosomal storage disease proteins and methods of use thereof
15 Jun 21
Provided are substantially dephosphorylated forms of lysosomal storage disease (LSD) proteins, including dephosphorylated forms of iduronate-2-sulfatase (IDS, or I2D) and iduronidase (IDU), having increased ability to traverse or penetrate the blood brain barrier (BBB) relative to phosphorylated forms of the protein, and p97 conjugates thereof.
Timothy Z. Vitalis, Reinhard Gabathuler
Filed: 2 Apr 18
Utility
Treatment of Gaucher Disease
22 Apr 21
Disclosed are therapeutic payloads comprising p97 fragments coupled with active agents having blood-brain barrier (BBB) transport activity, including variants and combinations thereof, to facilitate delivery of therapeutic or diagnostic agents across the BBB.
Mei Mei Tian, Mark Day
Filed: 18 May 19
Utility
Bifunctional Blood Brain Therapies
18 Feb 21
Disclosed are therapeutic payloads comprising p97 fragments coupled with active agents having blood-brain barrier (BBB) transport activity, including variants and combinations thereof, to facilitate delivery of therapeutic or diagnostic agents across the BBB.
Mei Mei Tian
Filed: 21 Mar 19
Utility
Fragments of P97 and Uses Thereof
2 Dec 20
Provided are fragments of human p97 (melanotransferrin) polypeptides having blood-brain barrier (BBB) transport activity, including variants and combinations thereof, conjugates comprising the p97 fragments, and related methods of use thereof, for instance, to facilitate the delivery of therapeutic or diagnostic agents across the BBB and into the central nervous system.
Timothy Z. Vitalis, Reinhard Gabathuler
Filed: 12 Aug 20
Utility
Fragments of P97 and uses thereof
14 Sep 20
Provided are fragments of human p97 (melanotransferrin) polypeptides having blood-brain barrier (BBB) transport activity, including variants and combinations thereof, conjugates comprising the p97 fragments, and related methods of use thereof, for instance, to facilitate delivery of therapeutic or diagnostic agents across the BBB.
Timothy Z. Vitalis, Reinhard Gabathuler
Filed: 7 May 18
Utility
P97-IDS Fusion Proteins
26 Aug 20
Provided are fusion proteins between p97 (melanotransferrin) and iduronate-2-sulfatase (IDS), and related compositions and methods of use thereof, for instance, to facilitate delivery of IDS across the blood-brain barrier (BBB) and/or improve its tissue penetration in CNS and/or peripheral tissues, and thereby treat and/or diagnose Hunter Syndrome (Mucopolysaccharidosis type II; MPS II) and related lysosomal storage disorders, including those having a central nervous system (CNS) component.
Timothy Z. Vitalis, Reinhard Gabathuler
Filed: 21 Jun 19
Utility
Use of P97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
20 Jul 20
The present invention provides for compositions and methods for treating, ameliorating or preventing a lysosomal storage disease by administering to a patient suffering front a lysosomal storage disease a P97 conjugated with an enzyme which is capable of transportation into the lysosomes of cells on either sides of the blood brain barrier.
Christopher M. Starr, Todd Zankel
Filed: 27 Feb 17
Utility
Use of P97 As an Enzyme Delivery System for the Delivery of Therapeutic Lysosomal Enzymes
17 Jun 20
The present invention provides for compositions and methods for treating, ameliorating or preventing a lysosomal storage disease by administering to a patient suffering from a lysosomal storage disease a P97 conjugated with an enzyme which is capable of transportation into the lysosomes of cells on either side of the blood brain barrier.
Christopher M. Starr, Todd Zankel
Filed: 17 Oct 19
Utility
P97 Fusion Proteins
16 Oct 19
Provided are p97 (melanotransferrin)-trastuzumab fusion proteins and related methods of use thereof, for instance, to facilitate delivery of trastuzumab across the blood-brain barrier (BBB) and/or improve tissue penetration of the antibody in CNS and peripheral tissues, and thereby treat and/or diagnose HER2-positive cancers, including those of the central nervous system (CNS).
Timothy Z. Vitalis, Reinhard Gabathuler
Filed: 9 Feb 19
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first